Back

Cardiopulmonary fitness and cancer therapy-related cardiac dysfunction defined by CMR: insights from the EMBRACE-MRI study

28 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Predicting cancer therapy–related cardiac dysfunction: from artificial intelligence-enabled assessment to risk refinement Cardio-Oncology ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Trecy Goncalves

University Health Network of Toronto, Toronto (Canada)

6 More presentations in this session

Presentation thumbnail
Baseline early diastolic mitral annular velocities and cancer therapy related cardiac dysfunction in HER2 therapy
Mr A. Chowdhury (Clayton, AU)
Abstract Slides
Presentation thumbnail
Incremental value of TAPSE added to HFA-ICOS for ESC-Defined Cancer Therapy–Related Cardiac Dysfunction
Doctor N. Espinola-Zavaleta (Mexico City, MX)
Abstract Slides Video
Presentation thumbnail
Incidence and severity of cancer-therapy-related cardiac dysfunction during contemporary breast cancer therapy in a real-world cohort
Doctor V. Vinje (Nordbyhagen, NO)
Abstract Slides Video
Presentation thumbnail
Machine learning-driven probability of cancer therapy–related cardiac dysfunction in patients with non-Hodgkin lymphoma
Doctor D. Bursacovschi (Chisinau, MD)
Abstract Slides
Presentation thumbnail
Agreement between manual and AI-enhanced echocardiographic assessment of cancer therapy-related cardiac dysfunction in patients with early breast cancer
Mr E. Orstad (Nordbyhagen, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Predicting cancer therapy–related cardiac dysfunction: from artificial intelligence-enabled assessment to risk refinement

The Event

Event poster

ESC Congress 2026

28 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Myocardial work and exercise LVEF as predictors of impaired cardiorespiratory fitness in breast cancer patients
18 May 2025
thumbnail
Congress Presentation
Differences in the prevalence of cardiovascular toxicity in a cohort of female breast cancer patients according to the different cardiotoxicity definitions
28 August 2023
thumbnail
Congress Presentation
The effect of sacubitril/valsartan on functional disability and skeletal muscle injury during breast cancer therapy: insights from the PRADA II trial
29 August 2026
thumbnail
Congress Presentation
Surveillance of left ventricular function among asymptomatic cancer survivors
31 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources